We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Targeted NGS Panel For Constitutional Cytogenetics Research
Product News

Targeted NGS Panel For Constitutional Cytogenetics Research

Targeted NGS Panel For Constitutional Cytogenetics Research
Product News

Targeted NGS Panel For Constitutional Cytogenetics Research


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Targeted NGS Panel For Constitutional Cytogenetics Research"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Oxford Gene Technology (OGT) has developed a targeted NGS panel for constitutional cytogenetics research. The new CytoSure™ NGS panel—launching early in 2020—is designed to combine the strengths of microarrays and NGS to deliver a comprehensive all-in-one assay. The new panel, in conjunction with OGT’s popular Interpret analysis software aims to facilitate the accurate and confident detection of loss of heterozygosity (LOH), mosaicism and copy number variants (CNVs), in addition to those more traditionally assayed by NGS, single nucleotide variants (SNVs) and insertions/deletions (indels).

Featuring the most up-to-date content for Intellectual Disability (ID) and Developmental Delay (DD), the new targeted NGS panel and Interpret software is designed to enable users to detect even small (single exon) CNVs accurately — something that is has been challenging with NGS and hence a major step forward for the technology.

Emma Shipstone, EVP, Marketing at OGT commented, “We have developed our CytoSure NGS panel to meet the increasing desire of labs to transition from microarrays to NGS and obtain as much information as possible from a single assay. NGS technologies have traditionally struggled with CNV detection, but thanks to OGT’s panel design expertise and advanced software algorithms, we have overcome these challenges.”


Advertisement